Evaxion has appointed Dr Helen Tayton-Martin as new Chief Executive Officer, CEO. She will take up her new position on November 24, 2025, and simultaneously step down from Evaxion’s Board of Directors. Prior to Adaptimmune, Dr. Tayton Martin spent 15 years working within the pharma, biotech and consulting environments for various companies. She also previously served as a non-executive director of Trillium Therapeutics from October 2017 through to the sale of the company in November 2021.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion Biotech price target raised to $11 from $6 at Lake Street
- Buy Recommendation for Evaxion Biotech Amid Promising Phase 2 Study Results and Future Potential
- Evaxion Biotech trading resumes
- Evaxion Biotech trading halted, volatility trading pause
- Evaxion Biotech Expands Capital Through ADS Sales and Warrant Exercises